Relay Therapeutics Launches Public Offering of Common Stock
Relay Therapeutics, Inc. (NASDAQ: RLAY), a pioneering clinical-stage precision medicine company dedicated to transforming drug discovery, is thrilled to announce the start of a public offering aimed at raising $200 million by issuing shares of its common stock. This offering includes an option for underwriters to acquire an additional 15% of shares, reflecting strong confidence in the demand for their innovative solutions.
Leading the Way in Drug Discovery
At Relay Therapeutics, the mission to revolutionize drug discovery is actively underway. By leveraging cutting-edge computational technologies alongside experimental methods, the company distinguishes itself as a frontrunner in the biotech field. Their unique Dynamo platform exemplifies this innovative approach, designed to facilitate the discovery of transformative therapies while addressing challenging protein structures that have previously posed significant hurdles.
Offering Details
Goldman Sachs & Co. LLC, TD Cowen, Stifel, and BofA Securities are leading the charge as joint book-running managers for this offering, showcasing the strength of Relay Therapeutics’ strategic partnerships. The proceeds from each share sold will support the company’s goal of enhancing its drug discovery capabilities, particularly in oncology and genetic diseases.
Market Conditions and Future Outlook
This public offering is subject to market conditions, and while specific terms and timelines cannot be guaranteed, Relay Therapeutics remains hopeful about successfully completing this capital-raising effort. The funding generated from this offering is expected to expedite research and development pipelines, potentially leading to groundbreaking therapies for patients around the globe.
Relay Therapeutics’ Dedication to Innovation
Relay Therapeutics’ commitment to redefining the possibilities in drug development is evident in its ongoing projects. With a comprehensive portfolio focused on difficult-to-drug proteins, the company is dedicated to discovering small molecule therapeutics aimed at oncology and genetic disorders. Each initiative reflects a strong commitment to enhancing patient outcomes through thorough scientific research and advanced technological methods.
Exploring the Dynamo Platform
The Dynamo platform is a fundamental aspect of Relay’s innovative strategy, empowering the company to transcend traditional drug discovery limitations. By integrating various computational techniques, the platform is designed to identify and optimize therapeutic compounds that could have a significant clinical impact. This proactive approach to innovation positions Relay at the forefront of developing therapies for complex diseases.
The Future of Relay Therapeutics
As Relay Therapeutics embarks on this new chapter with the proposed public offering, it is motivated by the vision of advancing precision medicine. The anticipated capital will not only strengthen research initiatives but also facilitate the introduction of new therapies for patients in need, solidifying the company’s position as a leader in the biotech industry.
Contact Information for the Company
Investors and members of the media are encouraged to reach out to Relay Therapeutics for inquiries. Megan Goulart is the primary contact for investors and can be reached at 617-545-5526 or via email at mgoulart@relaytx.com. For media inquiries, Dan Budwick is available at 973-271-6085 or dan@1abmedia.com.
Frequently Asked Questions
What is the primary aim of Relay Therapeutics' public offering?
The offering aims to raise funds to enhance their drug discovery research and development efforts in precision medicine.
Who are the managers handling the public offering?
Goldman Sachs & Co. LLC, TD Cowen, Stifel, and BofA Securities are the joint book-running managers for this public offering.
What is the significance of the Dynamo platform?
The Dynamo platform is Relay Therapeutics’ innovative tool that merges computational and experimental strategies to discover new therapies targeting challenging proteins.
In which areas is Relay Therapeutics focusing its research?
Relay Therapeutics is primarily focusing on oncology and genetic diseases, working to develop small molecule therapies that address unmet medical needs.
How can interested parties learn more about the public offering?
Details regarding the offering will be provided in the preliminary prospectus supplement filed with the SEC and will be accessible through their dedicated channels.
